Claritin OTC Switch In Pediatric Populations Could Pose Concerns For NDAC
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members may be hesitant to favor an Rx-to-OTC switch of Schering-Plough's Claritin franchise for younger pediatric patients